By calculating each patient’s exact radioactive iodine dose based on their thyroid size and uptake, doctors delivered 541 MBq for Graves' disease and 826 MBq for toxic nodules, which successfully normalized thyroid function in everyone within six months without needing a second treatment.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled mean administered RAI activity required to achieve target absorbed doses of 200–300 Gy in Graves' disease and toxic adenoma across multiple dosimetry protocols.
A systematic review and meta-analysis of all studies using MIRD-based dosimetry to calculate RAI activity for Graves' disease (target 200 Gy) and toxic adenoma (target 300 Gy), reporting mean administered activity, thyroid mass, and uptake parameters.
Whether the mean RAI activity of 541 MBq for Graves' disease and 826 MBq for toxic adenoma leads to better outcomes than fixed-dose regimens.
A double-blind RCT comparing two groups: one receiving dosimetry-based RAI (mean 541 MBq for Graves', 826 MBq for adenoma) and another receiving fixed-dose RAI (555 MBq for Graves', 740 MBq for adenoma), with primary outcome: euthyroid status at 6 months.
The consistency of administered RAI activity needed to achieve target absorbed doses in real-world clinical practice.
A prospective cohort of 400 patients with Graves' disease or toxic adenoma treated with dosimetry-based RAI, recording thyroid mass, uptake, effective half-life, and administered activity to determine mean values and variability.
Whether patients requiring higher or lower RAI activity differ in baseline characteristics.
A case-control study comparing 50 patients who received >700 MBq with 50 who received <400 MBq for Graves' disease, analyzing thyroid volume, iodine uptake, and TSH receptor antibody levels.
The distribution of administered RAI activities in a population treated with dosimetry-based RAI.
A cross-sectional survey of 300 patients treated with dosimetry-based RAI, recording administered activity, thyroid volume, and uptake to describe the range and mean values.